Welcome

Overview and Introduction to Genentech (gRED)

Oncology Pipeline Overview

Cancer Immunotherapy

Q&A

Karl Mahler, Head of Investor Relations and Roche Group Planning

Michael Varney, Head of Genentech Research and Early Development

Stuart Lutzker, Vice President, Oncology Research and ad interim Head of Early Clinical Development for gRED

Ira Mellman, Vice President, Cancer Immunology and Immunology for gRED